No Data
If EPS Growth Is Important To You, NCS Testing Technology (SZSE:300797) Presents An Opportunity
Ncs Testing Technology (300797.SZ): Expected gross margin will remain relatively stable.
On December 17, GLONGHUI reported that Ncs Testing Technology (300797.SZ) recently indicated during its investor relations activities that, according to the company's semi-annual report data, the gross margin for the company's testing Business was 46.1%, compared to 43.6% in the same period last year, both within the normal range for the company's testing Business gross margin, which experiences some fluctuations each year due to reasons such as collection and amortization. The company focuses on enhancing profitability and is accelerating the operational launch of constructed laboratories, intending to dilute fixed costs through increased Business volume. It is expected that, in the future, as personnel costs rise and the marginal utility of diluting fixed costs decreases, the gross margin will remain relatively stable.
Ncs Testing Technology (300797.SZ): The overall external testing market environment currently has little impact on Ncs Testing Technology's business.
On December 17, Glonghui reported that Ncs Testing Technology (300797.SZ) recently stated in investor relations activities that the company is committed to materials testing business, with a strong technical foundation in the field of Metal testing, especially in the testing of high-performance Metal materials such as high-temperature Alloys. Due to certain thresholds and qualification requirements for Metal materials testing, and the growing demand for testing in the target segmented market, the current overall market environment for external testing does not significantly impact Ncs Testing Technology's testing business.
Ncs Testing Technology (300797.SZ): The Zhuozhou laboratory plans to complete the overall acceptance by the end of December.
On December 17, Gelonghui reported that Ncs Testing Technology (300797.SZ) recently indicated during an investor relations event that currently, the Kunshan and Qingdao laboratories are operating steadily, the Shenyang laboratory has fully commenced its testing services since August, and both the Xi'an and Zhuzhou laboratories have obtained CMA qualifications for trial operations. The Zhuozhou laboratory is scheduled to complete its overall acceptance by the end of December. In the future, the company will continue to advance its national layout based on market conditions and development plans, further accelerate the production and effectiveness of established laboratories, and lay a solid foundation for the company's long-term healthy development.
gtja: The government is offering price discounts on domestic products for procurement, which is bullish for domestic scientific instruments.
Currently, as long as the product is produced in our country, it is considered a domestic product in government procurement activities.
Ncs testing technology (300797.SZ): As of the third quarter of 2024, the company's research and development expenses were 85.0161 million yuan, a year-on-year increase of 33.13%.
Gelonghui November 27th | ncs testing technology (300797.SZ) Investor Relations stated that the company has an internal research institute with over one hundred research and development personnel. At the same time, the company continues to increase its research and development investment. As of the third quarter of 2024, the company's research and development expenses were 85.0161 million yuan, a year-on-year increase of 33.13%.
NCS Testing Technology Co., Ltd.'s (SZSE:300797) Popularity With Investors Under Threat As Stock Sinks 26%
